OxCan utilizes machine learning algorithms and liquid biopsy techniques to detect lung cancer at an early stage through a simple blood test. This approach addresses the critical need for timely diagnosis, improving treatment outcomes and survival rates for lung cancer patients.
Funding
$11M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Lung cancer is often diagnosed at advanced stages, leading to poorer treatment outcomes and reduced survival rates. Current screening methods are invasive, expensive, and not suitable for widespread, frequent use. This results in delayed diagnosis and missed opportunities for curative treatment.
Solution
OxCan is developing a liquid biopsy test that uses machine learning algorithms to detect lung cancer early through a simple blood draw. The DEcancer platform analyzes biomarkers in the blood to identify signs of lung cancer at its earliest stages. This non-invasive approach aims to enable earlier diagnosis, improving the chances of successful treatment and increasing survival rates for lung cancer patients.
Target Audience
The primary target audience includes healthcare providers, hospitals, and individuals at high risk for lung cancer who would benefit from early and frequent screening.
Features
- Proprietary DEcancer platform utilizing machine learning for biomarker analysis
- Non-invasive liquid biopsy technique using a standard blood sample
- Early detection of lung cancer biomarkers for timely diagnosis
- Longitudinal monitoring capabilities to track disease progression